MiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells $17,732.40 in Stock

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $8.40, for a total transaction of $17,732.40. Following the sale, the insider now directly owns 265,271 shares in the company, valued at approximately $2,228,276.40. The trade was a 0.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

MiMedx Group Price Performance

MDXG stock opened at $8.09 on Thursday. The business’s fifty day moving average price is $8.66 and its 200 day moving average price is $7.75. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a market capitalization of $1.19 billion, a PE ratio of 14.71 and a beta of 1.97. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. On average, sell-side analysts anticipate that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Analyst Ratings Changes

Several research firms have issued reports on MDXG. StockNews.com cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price objective on shares of MiMedx Group in a research report on Thursday, February 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, MiMedx Group has a consensus rating of “Buy” and an average target price of $12.00.

Hedge Funds Weigh In On MiMedx Group

Several institutional investors have recently modified their holdings of MDXG. Paradigm Capital Management Inc. NY boosted its holdings in MiMedx Group by 0.5% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company’s stock valued at $45,082,000 after purchasing an additional 22,131 shares during the period. Cannell Capital LLC boosted its stake in shares of MiMedx Group by 1.1% in the 4th quarter. Cannell Capital LLC now owns 3,639,545 shares of the company’s stock valued at $35,012,000 after buying an additional 40,235 shares during the period. First Light Asset Management LLC acquired a new position in shares of MiMedx Group during the fourth quarter worth about $32,168,000. Geode Capital Management LLC increased its stake in shares of MiMedx Group by 1.6% during the third quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company’s stock worth $16,518,000 after buying an additional 44,254 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of MiMedx Group by 18.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company’s stock worth $17,360,000 after buying an additional 280,327 shares during the period. Institutional investors and hedge funds own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.